SCHEMBL10244298

SCHEMBL10244298

CCN(CCNC(=O)OC)C(C)c1c(OCc2ccccc2)cccc1OCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.41
MTNR1A P48039 3/20 0.41
MTNR1B P49286 2/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
BRD4 O60885 1/20 0.40
SGMS2 Q8NHU3 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
ACHE P22303 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 1/20 0.38
MRGPRX4 Q96LA9 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243525 0.83 ALOX5 (0.54) NPC1RAB9ASMN1; SMN2L3MBTL1MAPT
SCHEMBL10244300 0.83 MTNR1A (0.48) ALDH1A1MTNR1AMTNR1BNPC1RAB9A
SCHEMBL334872 0.79 MAPT (0.45) TDP1L3MBTL1MAPTMAPK1
SCHEMBL10243497 0.79 SLC22A1 (0.43) ALDH1A1MTNR1AMTNR1BSMN1; SMN2
SCHEMBL10243705 0.78 HCRTR1 (0.43) KDM4ESMN1; SMN2L3MBTL1
SCHEMBL10243117 0.78 L3MBTL1 (0.41) ALDH1A1MTNR1AMTNR1BL3MBTL1
SCHEMBL10243869 0.75 BCHE (0.37) ALDH1A1ACHE
SCHEMBL10243821 0.74 OPRK1 (0.46) KDM4EMTNR1AMTNR1BRAB9AACHE
SCHEMBL10243634 0.73 TSHR (0.40) KDM4EALDH1A1MTNR1AMTNR1B
SCHEMBL10243454 0.73 KDM4E (0.37) KDM4EL3MBTL1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 TDP1 2672/4885KDM4E 128/4885ALDH1A1 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.